Proceeds Purposes Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study.
M&A Terms
Venture Investor Forbion Capital Partners (FKA ABN)